Share Name Share Symbol Market Type Share ISIN Share Description
Silence Therapeutics Plc LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.00 -0.45% 438.00 428.00 434.00 446.00 428.00 440.00 58,462 16:35:29
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -20.5 -26.2 - 342

Silence Therapeutics Share Discussion Threads

Showing 50251 to 50275 of 50950 messages
Chat Pages: Latest  2014  2013  2012  2011  2010  2009  2008  2007  2006  2005  2004  2003  Older
DateSubjectAuthorDiscuss
11/10/2017
07:32
They're certainly trying to hammer home the point on the patents and Alny. This morning's rns is I think the first comment Silence has made on Patisiran since the recent news from Alny on its progress.
1gw
11/10/2017
07:25
The pieces continue to be put into place ref the sale of the company imo. News this morning layering the icing on the cake.
richie666
05/10/2017
11:16
Except that Griffiths has already declared above 29% so hasn't got another declaration to make on the upside unless he wants to bid for the company himself. Keith has got capacity to buy more and I agree he would be likely to be made an insider and asked to commit to support any deal that the board wanted to recommend. So I took their latest declarations (as of 20th September) as evidence that a deal wasn't close to conclusion at that time. The problem for your theory though is that the absence of buying is not a "stopping time" - it can only be disproved. Keith went through 19% in May 2016 I think, and was only shown "still" to be buying 16 or so months later when he declared going through 20% in September 2017.
1gw
05/10/2017
10:41
There is also the possibility of all paper merger with ARWR. Dont discount that.Clue here will be no more buying by Griffiths and related parties. With his stake size he will no doubt be made inside on any deal.
richie666
05/10/2017
08:52
I suppose big pharma might be a more equal match, in terms of legal resources for a patent battle, for Alny than Silence would be by itself. So if Silence does have a reasonable (but not cast iron) case against Alny then it might be more deliverable with big pharma backing and hence more valuable on a risked basis to big pharma than to Silence. I wonder if Capital Markets day is as much about setting out Silence's stall to potential bidders, as it is about informing its own shareholders and the wider investment community about the company. I note that "media" feature in the target audience: "a Capital Markets event for investors, analysts and media".
1gw
05/10/2017
05:40
Well if RNAi is really now taking off as a therapy then big pharma could be looking for further access too
rogen83
05/10/2017
01:31
Hope you are on the money R83 I keep taking a look the morning after (from Aus) and I half expect my golden touch to have a reverse effect. This time though added my all in at 197, so nice to see a little nudge up from there. Will ALNY bite the bullet and make a bid? Or will their stubborn CEO stick to his guns and spend the buy out money on defending his corner instead? Ideally a bit of steady ramp in the price for now and then a bid at the top end of the bid range. Can we get that lucky? GLA
ukeagle2aus
04/10/2017
15:35
There isn’t much to derail this near term. On the contrary you can sense the sentiment building quite nicely - Alnylam phase 3 was a game changer
rogen83
04/10/2017
14:25
I guess the question is whether they can keep the excitement going until the capital markets event on 14th November, and indeed whether if 200p holds the excitement might build towards that event as momentum players come in (I keep hoping for some of this). While I feel a certain temptation to take some profit above 200p, I'm not sure there's any obvious near-term catalyst for a meaningful pullback until 14th November, when there might be some "sell on the news" if the price has run up ahead of the event.
1gw
04/10/2017
14:16
200p breached
rogen83
04/10/2017
12:35
Great to see some 200p trades going through.
1gw
04/10/2017
06:04
MTFB news just in - she's gonna explode on today's news
gersemi
04/10/2017
05:54
Arrowhead at 10 month highs
rogen83
04/10/2017
03:48
Sold 50% and stuck it into MTFB (Beaufort Securities price target of 100p) though I do reckon there's still 300p in Silence, in time
gersemi
04/10/2017
03:41
This will make some long term posters smile (if they are still around). It must be at least 13 or 14 years since my first SR Pharma investment and I have a significant loss over that time. But I am at last ready to rekindle my interest and look to get something back as my poor sixth sense, finally says the end game is not to far away. It's a relatively lower investment than the heady days, but I have instructed my broker to cash in everything else and go all in on SLN. So Bare, Doc,Frog, Buzzzz,Graham Browns Dad,Billy,Tonester,Digger,Geoffmanana,Sawbones,JBD, Rick and lots of others from the past (apologies for my poor memory)let's hope this is ends up being one for the old crowd! GLA
ukeagle2aus
29/9/2017
05:52
How long till we get an approach? Tick tock
rogen83
28/9/2017
20:15
Another very nice day for ARWR shareholders (up another 7% to $4.22). I bottled it on analyst day, so no longer have a direct interest, but might it be enough to push SLN through 200p tomorrow?
1gw
28/9/2017
15:40
So close...
1gw
28/9/2017
14:45
1gw today is the day!
djnzloop
28/9/2017
10:04
Could this be the day the share price gets back through 200p?
1gw
28/9/2017
07:23
Arrowhead stake now worth £20m or 30p of SLNs share price Good work Ali
rogen83
27/9/2017
09:22
Looking at the various holdings notices, I wonder if RG, RK, Spreadex and ING positions are linked. RG & RK notified 4.63% spreadbet position as of 20th September. Spreadex has notified 5.49% spreadbet position also as of 20th September. ING notified 5.35% shares position as of 20th September. So is it likely that the spreadex position is mainly the other side of the RG & RK positions, while the ING position is mainly the underlying asset to cover spreadex? If that's correct then (most of) the ING and spreadex positions have to be ignored when calculating the number of voting rights controlled by top shareholders, otherwise there's double-counting. Given the 0.72% increase in the ING position as of 25th September, perhaps RG and/or RK have increased their spreadbet positions a bit as of that date.
1gw
26/9/2017
06:46
Arrowhead up 20% all good for sln investment
doc robinson
22/9/2017
19:52
Good call on Woodford, djnzloop. So with Woodford below the notifiable threshold, I think the major shareholders, with total positions including derivatives, are now: 29.2% Richard Griffiths 20.6% Robert Keith 11.9% Invesco (from Annual Report) 7.7% Henderson (from Annual Report) 5.3% ING 5.3% Aviva That's 80% held between the top 6 investors, with another 2.8% held by Ali (according to annual report). Is it credible that ING is holding that position for its own account, or is it likely to be on behalf of a client or as the underlying asset for a derivative offered to a client?
1gw
22/9/2017
17:59
The more held in just a few hands the better. Liquidity is going to be at a premium so any whiff of a deal and this is going to squeeze like buggary
rogen83
Chat Pages: Latest  2014  2013  2012  2011  2010  2009  2008  2007  2006  2005  2004  2003  Older
Your Recent History
LSE
SLN
Silence Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191122 17:53:51